<DOC>
	<DOC>NCT01130818</DOC>
	<brief_summary>The purpose of the study is to evaluate the safety and tolerability of single ascending (SAD) oral dose of GLPG0492 compared to placebo in healthy subjects. Also, pharmacokinetics (PK) and pharmacodynamics (PD) of GLPG0492 after single oral administration will be evaluated, and, if applicable, the maximum tolerated dose determined. Oral bioavailability (solution vs solid capsule fasting or fed) is evaluated in healthy elderly subjects.</brief_summary>
	<brief_title>First-in-Human Single Ascending Dose of GLPG0492</brief_title>
	<detailed_description />
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<criteria>healthy male, age 1850 years (young subjects) OR ≥60 years (elderly subjects) BMI between 1830 kg/m², inclusive nonsmoker elevated PSA drug or alcohol abuse</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2010</verification_date>
	<keyword>Safety</keyword>
	<keyword>Tolerability</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Bioavailability (solid vs solution, fasting vs fed)</keyword>
	<keyword>Young healthy subjects</keyword>
	<keyword>Elderly healthy subjects</keyword>
</DOC>